Does Pentraxin-3 contribute to the reduction of low-density lipoprotein levels by statin therapy?
Pentraxin-3 and low-density lipoprotein after statin therapy
Abstract
Statins have been shown to decrease inflammatory markers, especially high sensitivity C reactive protein (hsCRP), in a dose-dependent manner. Pentraxin-3 (PTX3) is another important inflammatory biomarker from the pentraxin family that provides useful prognostic information and facilitates diagnostics of cardiovascular diseases. This study investigated the effect of statin therapy on PTX3 and hsCRP concentrations and whether statins acted synergistically with PTX3 and hsCRP concentrations in lowering LDL-C. The study group consisted of 90 patients undergoing coronary angiography. The results showed that statins reduced PTX3 concentrations (p=0.031). PTX3 and hsCRP levels were significantly different between subclinical and severe stenosis groups (p=0.011 and p=0.009, respectively). Statin therapy was significantly associated with lower PTX3 and LDL-C levels in multiple logistic analyses. The probability that statin therapy would achieve target LDL-C values was highest in patients with low PTX3 values (OR=3.683, p=0.040), while multiplicative interaction was 23.3. The effect of statins on PTX3 reduction was higher than on hsCRP. It can be suggested that statin therapy was more successful in patients with low PTX3 values.
References
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun;73(24):e285–e350.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41:111-8.
Shavva VS, Mogilenko DA, Nekrasova EV, Trulioff AS, Kudriavtsev IV, Larionova EE, et al. Tumor necrosis factor α stimulates endogenous apolipoprotein A-I expression and secretion by human monocytes and macrophages: role of MAP-kinases, NF-κB, and nuclear receptors PPARα and LXRs. Mol Cell Biochem. 2018 Nov;448(1-2):211-23.
Liberale L, Carbone F, Montecucco F, Sahebkar A.. Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms. Int J Biochem Cell Biol. 2020 May;122:105735.
Margaritis M, Channon KM, Antoniades C. Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering. Antioxid Redox Signal. 2014;20(8):1198-215.
Hognestad A, Aukrust P, Wergeland R, Stokke O, Gullestad L, Semb AG, et al. Effects of Conventional and Aggressive Statin Treatment on Markers of Endothelial Function and Inflammation. Clin Cardiol. 2004;27:199–203.
Nissen S, Turzu M, Schoenhagen P, Crowe T, Sasiela W, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
Singh S, Suresh M, Voleti B, Agrawal A. The conection between C-reactive protein and atherosclerosis. Ann Med. 2008;40(2):110-20.
Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscl Thromb. 2004;11(2):62-72.
Baetta R, Lento S, Ghilardi S, Barbati E, Corsini A, Tremoli E, et al . Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation. Vasc Pharmacol. 2015;67-69:38-47.
Kim J, McEvoy JW, Nasir K, Budoff MJ, Arad Y, Blumenthal RS, et al. Critical Review of High-Sensitivity C-Reactive Protein and Coronary Artery Calcium for the Guidance of Statin Allocation Head-to-Head Comparison of the JUPITER and St. Francis Heart Trials. Circ Cardiovasc Qual Outcomes. 2014;7(2):315-22.
Pearson TA, Mensah GA, Alexander RW, Anderson JL,Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4.
Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-densitylipoprotein cholesterol. Clin Chem. 1982;28:1379–88.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – Full report. J Clin Lipidol. 2015 Mar-Apr;9(2):129-69.
Tyler J, VanderWeele, Mirjam J, Knol. A Tutorial on Interaction. Epidemiol Methods. 2014;3(1):33–72.
Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome. J Am Coll Cardiol. 2009;54:293-302.
Iwata A, Miura S, Tanaka T, Ike A, Sugihara M, Nishikawa H, et al. Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin. Coron Artery Dis. 2012;23(5):315-21.
Ohbayashi H, Miyazawa C, Miyamoto K, Sagara M, Yamashita T, Ouda R. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscl Thromb. 2009;16(4):490-500.
Shindo A, Tanemura H, Yata K, Hamada K, Shibata M, Umeda Y, et al. Inflammatory biomarkers in atherosclerosis: pentraxin 3 can become a novel marker of plaque vulnerability. PLoS One. 2014;9:e100045.
Inoue K, Kodama T, Daida H. Pentraxin 3: A novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med. 2012;2012:657025.
Zhao Y, Feng G, Wang Y, Yue Y, Zhao W. A key mediator, PTX3, of IKK/IκB/NF-κB exacerbates human umbilical vein endothelial cell injury and dysfunction. Int J Clin Exp Pathol. 2014;7(11):7699-707.
Lin R, Liu J, Peng N, Yang G, Gan W, Wang W. Lovastatin reduces nuclear factor κB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull. 2005;28(9):1630-4.
Rao A, Milbrandt E. To JUPITER and beyond: statins, inflammation, and primary prevention. Critical Care. 2010;14:310.
Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive proteine levels: the pravastatin inflammation /CRP evaluation (PRINCE): a randomised trial and cohort study. JAMA. 2001;286(1):64-70.
Bosutti A, Grassi G, Zanetti M, Aleksova A, Zecchin M, Sinagra G, et al. Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66 (ShcA) in pacemaker-implanted patients. Clin Exp Med. 2007;7(1):16-23.
Zanetti M, Zenti M, Barazzoni R, Zardi F, Semolic A, Messa MG, et al. HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. PLoS One. 2014 Jul 11;9(7):e101290.
